Gemigliptin/rosuvastatin

Drug Profile

Gemigliptin/rosuvastatin

Alternative Names: Rosuvastatin/gemigliptin; ZemiStatin

Latest Information Update: 17 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator LG Life Sciences
  • Developer LG Chem
  • Class Antihyperglycaemics; Fluorobenzenes; Piperidines; Pyrimidines; Small molecules; Sulfonamides
  • Mechanism of Action CD26 antigen inhibitors; HMG-CoA reductase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Dyslipidaemias; Type 2 diabetes mellitus

Most Recent Events

  • 09 Jun 2017 Efficacy and adverse events data from a phase III trial in Type-2 diabetes mellitus and Dyslipidaemias presented at the 77th Annual Scientific Sessions of the American Diabetes Association (ADA-2017)
  • 25 Jul 2016 Phase III development is ongoing in South Korea (LG Life Sciences pipeline, July 2016)
  • 01 Mar 2016 LG Life Sciences completes a phase III trial in Dyslipidaemias and Type-2 diabetes mellitus in South Korea (NCT02126358)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top